Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,882
Views
12
CrossRef citations to date
0
Altmetric
Research Article

ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer

Zheng Liua Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaView further author information
,
Kejia Zhaoa Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaView further author information
,
Shiyou Weia Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaView further author information
,
Chengwu Liua Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaView further author information
,
Jiankang Zhouc State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaView further author information
,
Qiheng Gouc State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaView further author information
,
Xia Wud Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaView further author information
,
Zhenyu Yanga Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaView further author information
,
Yanbo Yanga Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaView further author information
,
Yong Penga Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, China;c State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaView further author information
,
Qing Chenge Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USAView further author information
&
Lunxu Liua Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 1758003 | Received 15 Sep 2019, Accepted 30 Mar 2020, Published online: 06 May 2020

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Adriana Petrazzuolo, M. Chiara Maiuri, Laurence Zitvogel, Guido Kroemer & Oliver Kepp. (2022) Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 11:1.
Read now

Articles from other publishers (11)

David John McMahon, Ronan McLaughlin & Jarushka Naidoo. (2024) Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review. Cancers 16:3, pages 527.
Crossref
Ea Maria Tønning Tønnesen, Magnus Stougaard, Peter Meldgaard & Johanne Lade-Keller. (2024) Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy . Journal of Clinical Pathology 77:1, pages 54-60.
Crossref
Zhe Huang, Huan Yan, Liang Zeng, Qinqin Xu, Wenhuan Guo, Shaoding Lin, Wenjuan Jiang, Zhan Wang, Li Deng, Haoyue Qin, Xing Zhang, Fan Tong, Ruiguang Zhang, Zhaoyi Liu, Lin Zhang, Xiaorong Dong, Nong Yang & Yongchang Zhang. (2023) Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1 -Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study . JCO Precision Oncology:7.
Crossref
Jiawei Xu, Yiyi Xiong, Zhou Xu, Hongquan Xing, Lingyun Zhou & Xinyi Zhang. (2022) From targeted therapy to a novel way: Immunogenic cell death in lung cancer. Frontiers in Medicine 9.
Crossref
Zheng Gao, Jia-Feng Chen, Xiao-Gang Li, Ying-Hong Shi, Zheng Tang, Wei-Ren Liu, Xin Zhang, Ao Huang, Xuan-Ming Luo, Qiang Gao, Guo-Ming Shi, Ai-Wu Ke, Jian Zhou, Jia Fan, Xiu-Tao Fu & Zhen-Bin Ding. (2022) KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma. Cancer Cell International 22:1.
Crossref
Giulia Petroni, Aitziber Buqué, Lisa M. Coussens & Lorenzo Galluzzi. (2022) Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nature Reviews Drug Discovery 21:6, pages 440-462.
Crossref
Shuli Wei, Mangsha Hu, Yan Yang, Xiaojie Huang, Baizhou Li, Liren Ding & Pingli Wang. (2022) Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion. Frontiers in Oncology 12.
Crossref
Amanda J. W. Gibson, Adrian Box, Winson Y. Cheung, Michelle L. Dean, Anifat A. Elegbede, Desiree Hao, Aliyah Pabani, Randeep Sangha & Dafydd Gwyn Bebb. (2022) Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort. Current Oncology 29:3, pages 1967-1982.
Crossref
Karen Bräutigam, Elodie Kabore-Wolff, Ahmad Fawzi Hussain, Stephan Polack, Achim Rody, Lars Hanker & Frank Köster. (2021) Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines. Journal of Cancer Research and Clinical Oncology 147:10, pages 2923-2933.
Crossref
Dongsheng Yue, Juanjuan Qian, Zhipeng Chen, Bin Zhang, Peng Chen, Lei Zhang, Jingjing Li, Henghui Zhang & Changli Wang. (2021) Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1 -rearranged lung adenocarcinoma . Journal for ImmunoTherapy of Cancer 9:2, pages e001967.
Crossref
Liangliang Cai, Jianchun Duan, Li Qian, Zhijie Wang, Shuhang Wang, Sini Li, Chao Wang, Jie Zhao, Xue Zhang, Hua Bai & Jie Wang. (2020) ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer. Frontiers in Immunology 11.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.